Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards

Study Overview
=================
Brief Summary
-----------------
Hypomagnesemia is a common entity in the inpatient and outpatient setting. in previous retrospective study hypomagnesemic patients have higher mortality and longer hospitalization. whether hypomagnesemia is merely a marker of poor prognosis, or whether replacing it can improve outcomes is unclear. The current standard of care is to discharge these patients without workup or further treatment, even if patients had received intravenous therapy while hospitalized. The investigator wish to examine prospectively whether giving replacement therapy affects mortality, length of hospital stay and overall well-being. In order to replete intracellular levels and replete magnesium stores, magnesium should be given for several months.

Official Title
-----------------
Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards

Conditions
-----------------
Hypomagnesemia

Intervention / Treatment
-----------------
* Drug: Magnesium Citrate 100 MG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient admitted over the age of 18, has hypomagnesemia (magnesium level ≤1.9 mg/dL) and is able to give consent. Exclusion Criteria: A patient unable to give consent. A patient admitted for an elective procedure. A patient in critical condition or dying. Patients with advanced kidney disease with eGFR<15ml/min or on dialysis. Patients with severe diarrhea, precluding use of magnesium citrate. Patients already receiving magnesium supplements. Patients with severe malnutrition or life-threatening hypomagnesemia (serum level <1mg/dL), requiring intravenous and oral replacement of magnesium.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Experimental group<br>After initial intravenous treatment, participants (those with magnesium level ≥1 mg/dL) will be randomized, and oral magnesium therapy ( or no treatment) will be started. The experimental group will receive 400mg magnesium daily in two divided doses. Patients in the experimental group will be discharged with one month's supply of magnesium and continued for at least three months. | Drug: Magnesium Citrate 100 MG<br>* initial intravenous treatment: Patients with magnesium levels 1-1.5 mg/dL will receive 2-4 grams of magnesium sulfate in the first 24 hours. Patients with magnesium levels 1.6-1.9 mg/dL will receive 1 gram of magnesium sulfate. participants with magnesium level ≥1 mg/dL, will be randomized, and oral magnesium therapy, Magnesium Citrate, ( or no treatment) will be started, and continued for at least three months. The experimental group will receive 400mg magnesium daily in two divided doses.<br>* Other names: Diasporal;|
| No Intervention: Control group<br>control group will receive standard care (no treatment). Patient will have their blood tested and will come for follow up visit every month for 3 months after discharge. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| compare mortality | To compare mortality between the population receiving magnesium and the population receiving standard care: ie no replacement. | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hospitalization | Length in days of hospitalization. | one year |